Onyda XR June 25, 2024 On May 24, 2024, the FDA approved Onyda XR (clonidine hydrochloride), a liquid non-stimulant medication for attention deficit hyperactivity disorder (ADHD). Developed by Tris Pharma, Onyda XR is a centrally acting alpha 2 Read More
Compounding Pharmacies vs. Big Pharma: The Battle for Dominance in the Growing GLP-1 Market October 22, 2024
